Intelligent Bio Solutions Inc. (INBS)
| Market Cap | 3.77M -66.9% |
| Revenue (ttm) | 3.91M +33.3% |
| Net Income | -11.61M |
| EPS | -11.36 |
| Shares Out | 2.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,425 |
| Open | 1.550 |
| Previous Close | 1.550 |
| Day's Range | 1.540 - 1.594 |
| 52-Week Range | 1.520 - 24.900 |
| Beta | 4.17 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 4, 2026 |
About INBS
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporate... [Read more]
Financial Performance
In fiscal year 2025, Intelligent Bio Solutions's revenue was $3.05 million, a decrease of -1.90% compared to the previous year's $3.11 million. Losses were -$10.57 million, 4.06% more than in 2024.
Financial StatementsNews
Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry
Company has addressed final review items from penetration testing and finalized cybersecurity and software documentation
Intelligent Bio Solutions completes precision testing for drug screening system
Intelligent Bio Solutions (INBS) announced the completion of precision testing, a key component of the company’s FDA 510 submission for U.S. market clearance of its Intelligent Fingerprinting Drug Scr...
Intelligent Bio Solutions Slides: Corporate presentation
Intelligent Bio Solutions has posted slides in relation to its latest quarterly earnings report, which was published on July 21, 2026.
Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market
Precision testing confirms reproducibility across more than 1,600 tests, three production runs, and three independent testing sites Precision testing confirms reproducibility across more than 1,600 te...
Intelligent Bio Solutions Transcript: Planet MicroCap Las Vegas 2026
A non-invasive drug testing device using fingertip sweat delivers results in 10 minutes and features the industry's shortest detection window, targeting workplace impairment. The business is expanding globally, shifting manufacturing to Asia for higher margins, and is preparing for FDA submission in the U.S.
Intelligent Bio Solutions Slides: Investor presentation
Intelligent Bio Solutions has posted slides in relation to its latest quarterly earnings report, which was published on June 17, 2026.
Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry
Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings
Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing so...
Intelligent Bio Solutions initiates multi-site method comparison study
Intelligent Bio Solutions (INBS) announced the initiation of a multi-site method comparison study to support its FDA 510 submission for U.S. market clearance of its Intelligent Fingerprinting Drug Scr...
Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission
Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerprinting Drug Screening System Company expects to complete enrollment and data collection by the end ...
Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year
Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, build...
Intelligent Bio Solutions Quarterly report: Q3 2026
Intelligent Bio Solutions has published its Q3 2026 quarterly earnings report on May 13, 2026.
Intelligent Bio Solutions Earnings release: Q3 2026
Intelligent Bio Solutions released its Q3 2026 earnings on May 13, 2026, summarizing the period's financial results.
Intelligent Bio Solutions announces launch of validation study for IFDSS
Intelligent Bio Solutions (INBS) announced the launch of a validation study aimed at significantly reducing the analysis time of its Intelligent Fingerprinting Drug Screening System, IFDSS. The study ...
Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results
Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes
Intelligent Bio Solutions Slides: Investor presentation
Intelligent Bio Solutions has posted slides in relation to its latest quarterly earnings report, which was published on April 20, 2026.
Intelligent Bio Solutions announces completion of penetrating testing
Intelligent Bio Solutions (INBS) announced the successful completion of penetration testing as part of its upcoming FDA 510(k) submission. The testing identified no major vulnerabilities, verified the...
Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified
INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission INBS implements enhanced security architecture to protect test int...
Intelligent Bio completes initial drug screening system clinical cut-off study
Intelligent Bio Solutions (INBS) announced the successful completion of its initial clinical cut-off study supporting the company’s FDA 510(k) submission for U.S. market clearance of its Intelligent F...
Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market
Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability,...
Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing s...
Intelligent Bio Solutions manufactures, ships first readers with new partner
Intelligent Bio Solutions (INBS) announced the receipt and deployment of the first shipment of Intelligent Fingerprinting Drug Screening Readers manufactured under its new strategic manufacturing part...
Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry
Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026
Intelligent Bio Solutions announces partnership with Bouygues UK
Intelligent Bio Solutions (INBS) announced a partnership with Bouygues UK, a subsidiary of Bouygues Construction, a multi-billion-dollar global construction firm with 35,600 employees, for the deploym...
Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout
Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS's fingerprint drug testing t...